GGrantIndex
Sort

15,273 grants matching antimicrobial resistance

Mapping host-microbe-metabolite interactions in 3D to find diet-derived enhancers of immunity

$1,102,500
Robin Knight · University Of California, San Diego · DP1 · FY2019 · AT

Oxadiazole Inhibitors of Non-Stop Ribosome Rescue to treat MDR Neisseria gonorrhoeae

$1,100,543
Zachary David Aron · Microbiotix, Inc · R01 · FY2019 · AI

Advanced Development of a Combined Shigella-ETEC Vaccine

$1,098,552
Eileen M. Barry · University Of Maryland Baltimore · R01 · FY2025 · AI

Discovering antimicrobials acting against MDR pathogens

$1,095,522
Kim Lewis · Northeastern University · R01 · FY2024 · AI

Discovering antimicrobials acting against MDR pathogens

$1,095,522
Kim Lewis · Northeastern University · R01 · FY2025 · AI

Acne: a disease of lipid metabolism, microbiome and the immune response

$1,093,670
Robert L Modlin · University Of California Los Angeles · P50 · FY2023 · AR

Exploiting Riboswitch Sensors to Reveal Antibiotics Uptake and Retention in Gram Negative Bacteria

$1,090,845
Ronald R Breaker · Yale University · R01 · FY2021 · AI

Studies of Chemokine-Receptor Interactions with Chemokines and alarmins

$1,090,780
Joost J Oppenheim · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA

Acne: a disease of lipid metabolism, microbiome and the immune response

$1,089,937
Robert L Modlin · University Of California Los Angeles · P50 · FY2024 · AR

Rapid, Breath Volatile Metabolite-Based Diagnostic for In Vivo Identification and Antibiotic Resistance Profiling of Bacterial Pathogens in Ventilator-Associated Pneumonia

$1,089,217
Sophia Koo · Brigham And Women'S Hospital · R01 · FY2020 · AI

Optimized Combination Antimalarial Drug Therapy

$1,087,190
Paul D. Roepe · Georgetown University · R01 · FY2015 · AI

Drug resistance enablers and their role in antibiotic treatment failure

$1,085,284
Vaughn Cooper · Boston Children'S Hospital · U19 · FY2024 · AI

Short and long term outcomes of doxycycline versus TMP-SMX for SSTI treatment

$1,083,522
Loren G Miller · Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center · U01 · FY2021 · AI

Chemistry Core

$1,081,381
Timothy S Bugni · University Of Wisconsin-Madison · U19 · FY2020 · AI

Biochemistry of Energy-Dependent (Intracellular) Protein Degradation

$1,079,940
Michael Maurizi · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA

Point-of-care antimicrobial susceptibility testing based on simultaneous tracking of multi-phenotypic features of single bacterial cells

$1,079,736
Shaopeng Wang · Arizona State University-Tempe Campus · R01 · FY2022 · AI

Point-of-care antimicrobial susceptibility testing based on simultaneous tracking of multi-phenotypic features of single bacterial cells

$1,079,736
Shaopeng Wang · Arizona State University-Tempe Campus · R01 · FY2021 · AI

Clinical Trial for CA-MRSA Infections

$1,077,815
Denise Tritt · Olive View-Ucla Education And Res Inst · N01 · FY2012 · AI

Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negativebacterial infections

$1,076,832
David S Perlin · Hackensack University Medical Center · R01 · FY2022 · AI

Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negative bacterial infections

$1,076,832
David S Perlin · Hackensack University Medical Center · R01 · FY2021 · AI

AI-3 Inhibitors as treatment for bacterial infections

$1,075,870
Vanessa Sperandio · Ut Southwestern Medical Center · U01 · FY2012 · AI

Studies of Chemokine-Receptor Interactions with Chemokines and alarmins

$1,072,297
Joost J Oppenheim · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA

A multiscale approach to develop and apply fluoride efflux inhibitors to reverse oral dysbiosis and eliminate early childhood caries

$1,071,751
Randy B. Stockbridge · University Of Michigan At Ann Arbor · RM1 · FY2025 · DE

Consortium for drug-resistant Gram-negative pathogen detection

$1,071,131
Lee W Riley · University Of California Berkeley · R01 · FY2019 · AI

Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negative bacterial infections

$1,070,621
David S Perlin · Hackensack University Medical Center · R01 · FY2019 · AI